Your browser doesn't support javascript.
loading
Malignant melanoma in Portuguese adult population: a scoping review of the real-world evidence.
Gouveia, Emanuel; de Sousa, Rita Teixeira; Aguiar, Sandra I; Gírio, Ana; Costa, Inês; Dionísio, Maria Rita; Moital, Inês.
Afiliação
  • Gouveia E; Department of Medical Oncology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
  • de Sousa RT; Department of Medical Oncology, Centro Hospitalar Universitário Lisboa Norte-Hospital de Santa Maria, Lisbon, Portugal.
  • Aguiar SI; Novartis Innovative Medicines International, Produtos Farmacêuticos S.A., Porto Salvo, Portugal.
  • Gírio A; Novartis Innovative Medicines International, Produtos Farmacêuticos S.A., Porto Salvo, Portugal. anasofia.veloso@novartis.com.
  • Costa I; Novartis Innovative Medicines International, Produtos Farmacêuticos S.A., Porto Salvo, Portugal.
  • Dionísio MR; Novartis Innovative Medicines International, Produtos Farmacêuticos S.A., Porto Salvo, Portugal.
  • Moital I; Novartis Innovative Medicines International, Produtos Farmacêuticos S.A., Porto Salvo, Portugal.
Clin Transl Oncol ; 2024 Jul 16.
Article em En | MEDLINE | ID: mdl-39012454
ABSTRACT

PURPOSE:

Malignant melanoma is an aggressive cancer, and there is a notable dearth on epidemiology, clinical and treatment characterization within the Portuguese population. We performed a scoping review to identify real-world evidence studies focused in Portuguese adult patients with malignant melanoma.

METHODS:

A comprehensive search was conducted. After screening, we described the studies by design, sample size, geographics, setting, population, and outcomes reported.

RESULTS:

The search yielded 54 studies, mainly retrospective (79.6%). The population assessed was heterogeneous varying from patients with melanoma in general to specific types of melanoma, or even more restricted to patients with specific conditions. The evidence found was mostly concerning clinical outcomes (n=46), patients' clinical profile (n=44) and demographic characterization (n=48). Treatment information was described in 30 studies whereas only 18 reported epidemiological parameters. Studies were mainly performed by the major oncology centers in Lisbon, Oporto and Coimbra, and only two evaluated the entire Portuguese population. To allow comparability, only studies including patients with cutaneous malignant melanoma were considered (13 of the 54) for outcomes evaluation analysis. Median OS varied from 18 to 36 months, assessed after melanoma treatment. Incidence was the most reported epidemiological parameter, confirming the increasing number of cutaneous malignant melanoma patients over the years. Only one study reported prevalence and four reported mortality rates.

CONCLUSIONS:

The evidence found confirms the lack of information about malignant melanoma in Portugal, highlighting the need of real-world studies to assess melanoma prevalence and incidence rates, current treatment approaches, and clinical characterization of these patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article